Gandouling通过调节肠道菌群来改善威尔逊病肝纤维化:一个随机,双盲,安慰剂受控试验
1The First Affiliated Hospital of Anhui University of Chinese Medicine, Shushan District, Hefei City, Anhui Province No. 117 Meishan Road Hefei Anhui 230031, China.
Bioscience of microbiota, food and health
|October 6, 2025
概括
甘露 (GDL) 补充剂显著改善了威尔逊病 (WD) 患者的肝纤维化和改变肠道微生物群. 这种治疗优化了肝硬度和微生物多样性,表明肝纤维化的潜在逆转.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 微生物组研究 微生物组研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 威尔逊病 (WD) 是一种遗传性疾病,导致铜积累,往往导致肝纤维化.
- 目前的治疗重点是去除铜,但控制肝纤维化进展仍然是一个挑战.
- 人们越来越认识到肠道微生物在肝病中的作用.
研究的目的:
- 调查Gandouling (GDL) 在改善WD患者肝纤维化指数方面的疗效.
- 探索GDL对WD患者肠道微生物群组成和多样性的影响.
- 评估GDL与常规WD治疗的结合作用.
主要方法:
- 一项为期48天的随机,双盲,安慰剂对照试验,涉及90名肝纤维化WD患者.
- 患者接受了常规的二甲硫酸盐加上GDL或安慰剂.
- 分析了治疗前和后的肝硬度 (FibroTouch),生化标志物和便样本的16S rRNA基因测序.
主要成果:
- GDL显著改善了肝硬度和非侵入性纤维化指标 (p<0.05).
- 肝酶 (ALT,AST,GGT),胆酸和纤维化标志物 (氨酸,拉米宁) 的显著减少在GDL中观察到.
- GDL治疗导致了微生物多样性的增加,益生菌的增加,以及肠道中致病细菌的减少.
结论:
- 结合标准WD治疗,GDL有效改善肝纤维化标志物.
- GDL 显示出显著的调节和重建肠道微生物群落的能力.
- 这些由GDL调节的肠道微生物群可能有助于逆转WD中的肝纤维化.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
637
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
637
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488

